Casas, JP;
Hingorani, AD;
(2012)
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
Lancet
, 379
(9822)
1214 - 1224.
10.1016/S0140-6736(12)60110-X.
![]() Preview |
PDF
1346393.pdf Download (329kB) |
Abstract
A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.
Archive Staff Only
![]() |
View Item |